Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

Hauschild A, Hassel JC, Ziemer M, Rutkowski P, Meier F, Flatz L, Gaudy-Marqueste C, Santinami M, Russano F, von Wasielewski I, Eigentler T, Maio M, Zalaudek I, Haferkamp S, Quaglino P, Welzel J, Weichenthal M, Elia G, Covelli A, Lorizzo K, Parca A, Neri D, Ascierto PA, Robert C, Schadendorf D, Kaehler KC

Open source

DOI: 10.1200/jco-26-00852
Published: 2026 Aug 11
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-26-00852,
  title = {Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.},
  author = {Hauschild A and Hassel JC and Ziemer M and Rutkowski P and Meier F and Flatz L and Gaudy-Marqueste C and Santinami M and Russano F and von Wasielewski I and Eigentler T and Maio M and Zalaudek I and Haferkamp S and Quaglino P and Welzel J and Weichenthal M and Elia G and Covelli A and Lorizzo K and Parca A and Neri D and Ascierto PA and Robert C and Schadendorf D and Kaehler KC},
  year = {2026},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco-26-00852},
  url = {https://doi.org/10.1200/jco-26-00852}
}

RIS

TY  - JOUR
TI  - Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.
AU  - Hauschild A
AU  - Hassel JC
AU  - Ziemer M
AU  - Rutkowski P
AU  - Meier F
AU  - Flatz L
AU  - Gaudy-Marqueste C
AU  - Santinami M
AU  - Russano F
AU  - von Wasielewski I
AU  - Eigentler T
AU  - Maio M
AU  - Zalaudek I
AU  - Haferkamp S
AU  - Quaglino P
AU  - Welzel J
AU  - Weichenthal M
AU  - Elia G
AU  - Covelli A
AU  - Lorizzo K
AU  - Parca A
AU  - Neri D
AU  - Ascierto PA
AU  - Robert C
AU  - Schadendorf D
AU  - Kaehler KC
PY  - 2026
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco-26-00852
UR  - https://doi.org/10.1200/jco-26-00852
ER  -

APA

A, H., JC, H., M, Z., P, R., F, M., L, F., C, G., M, S., F, R., I, V. W., T, E., M, M., I, Z., S, H., P, Q., J, W., M, W., G, E., A, C., K, L., A, P., D, N., PA, A., C, R., D, S., & KC, K. (2026). Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco-26-00852

Source records

pubmed · retrieved 2026-09-26T06:53:24.135Z
europe-pmc · retrieved 2026-09-26T06:53:24.160Z